Market Research Logo

Global Antibody Conjugates Drugs Market 2016-2020

About Antibody Drug Conjugates

ADCs, empowered monoclonal antibodies (mAbs), use chemical linkers with labile bonds to attach biologically active substances. ADCs target mAbs with the cancer killing ability of cytotoxic drugs, allowing sensitive discernment between healthy and diseased tissue.

Antibodies are the proteins produced by B-cells (from bone marrow) in the immune system. These proteins attach to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies that attach to different sites of an antigen. mAbs, complex proteins with high molecular weight, are monospecific as they are the clones of a single parent cell. They are of three types, chimeric, humanized, and fully human, and are often used for therapeutic and diagnostic purposes.

Technavio’s analysts forecast the global ADCs market to grow at a CAGR of 41.58% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global ADCs market for the period 2015-2020. To calculate the market size, the report considers revenue generated from the sales of ADCs used to treat cancer.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Antibody Drug Conjugates Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • F. Hoffmann-La Roche AG
  • Seattle Genetics Inc.
  • Takeda Pharmaceutical Company
Other prominent vendors
  • AbbVie
  • AbGenomics
  • ADC Therapeutics
  • Agensys
  • ALMAC Group
  • Ambrx
  • Astellas Pharma
  • AstraZeneca
  • Bayer HealthCare
  • CARBOGEN AMCIS
  • Celldex Therapeutics
  • Daiichi Sankyo
  • Endo Pharmaceuticals
  • Esperance Pharmaceuticals
  • Formation Biologics
  • Genmab
  • GlaxoSmithKline
  • Immunogen
  • Kairos Therapeutics
  • MedImmune
  • Mersana Therapeutics
  • Novartis
  • Oxford Biotherapeutics
  • Pfizer
  • Stemcentrx
  • Synthon Biopharmaceuticals
  • Zymeworks
Market driver
  • Robust late-stage pipeline
  • For a full, detailed list, view our report
Market challenge
  • High developmental costs
  • For a full, detailed list, view our report
Market trend
  • Strategic alliances
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Antibody Drug Conjugates Market 2016-2020
Technavio recognizes the following companies as the key players in the Global Antibody Drug Conjugates Market: F. Hoffmann-La Roche AG, Seattle Genetics Inc., and Takeda Pharmaceutical Company.
Other Prominent Vendors in the market are: AbbVie, AbGenomics, ADC Therapeutics, Agensys, ALMAC Group, Ambrx, Astellas Pharma, AstraZeneca, Bayer HealthCare, CARBOGEN AMCIS, Celldex Therapeutics, Daiichi Sankyo, Endo Pharmaceuticals, Esperance Pharmaceuticals, Formation Biologics, Genmab, GlaxoSmithKline, Immunogen, Kairos Therapeutics, MedImmune, Mersana Therapeutics, Novartis, Oxford Biotherapeutics, Pfizer, Stemcentrx, Synthon Biopharmaceuticals, and Zymeworks.
Commenting on the report, an analyst from Technavio’s team said: “Strategic alliances, in terms of collaboration and licensing, help co-develop and commercialize drugs in different regions. Co-development agreements between companies enable the use of technical expertise from both companies. It also allows the use of regulatory and development experience gained by one company for the support of the pipeline candidates of the other company. Such agreements ensure the in-flow of adequate funds for both the companies and help reduce the liability costs of individual companies in case of failures, attracting more venture investments.”
According to the report, products in the late pipeline stages will likely be launched during the forecast period. Some of these products include glembatumumab vedotin by Seattle Genetics, trastuzumab by Synthon Biopharmaceuticals, and SGN-35 by Takeda Pharmaceuticals. Some molecules are in the Phase I/II, preclinical, and discovery stages. ADCETRIS is currently under clinical trials for additional indications such as frontline mature T-cell lymphomas, B-cell lymphomas, and CD30-expressing conditions.
Further, the report states that the high developmental costs of antibody conjugates negatively impact the growth of the market.

Companies Mentioned

F. Hoffmann-La Roche AG, Seattle Genetics Inc., Takeda Pharmaceutical Company, AbbVie, AbGenomics, ADC Therapeutics, Agensys, ALMAC Group, Ambrx, Astellas Pharma, AstraZeneca, Bayer HealthCare, CARBOGEN AMCIS, Celldex Therapeutics, Daiichi Sankyo, Endo Pharmaceuticals, Esperance Pharmaceuticals, Formation Biologics, Genmab, GlaxoSmithKline, Immunogen, Kairos Therapeutics, MedImmune, Mersana Therapeutics, Novartis, Oxford Biotherapeutics, Pfizer, Stemcentrx, Synthon Biopharmaceuticals, Zymeworks.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
    • Assumptions
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Overview of ADCs
    • Antibodies
    • Evolution of mAb therapeutics
      • Table Comparison of small molecule and mAbs
      • Table Preparation of mAbs
    • Conjugated mAbs
    • History
      • Table Timeline of ADCs
    • Key components in ADCs
      • Table Key components
    • Next-generation ADCs
      • Table Components of next-generation ADCs
    • Advantages
      • Table Advantages of ADCs
    • Challenges
    • Outsourcing of ADCs manufacturing
    • Emergence of ADCs
      • Table Emergence of ADCs
    • Current marketed ADCs
      • Table Marked ADCs products
  • Pipeline portfolio
    • Table Pipeline portfolio of ADCs
    • Table Pipeline share of ADCs
    • Information on pipeline candidates
      • Table Market share of ADCs in clinical development
      • Table Few target antigens for ADCs in clinical development
      • Table Top five companies share in ADC pipeline
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global ADCs market 2015-2020 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by MOA
    • Table Global ADCs market segmentation by MOA
    • IgG1 antibodies
    • HER2 antibodies
  • Market segmentation by technologies used in ADCs
    • Seattle Genetics (SGEN) technology
    • ImmunoGen (IMGN) technology
      • Table Components in IMGN technology
    • Immunomedics (IMMU) technology
      • Table Share of ADCs technologies
  • Geographical segmentation
    • Table Global ADCs market by geography 2015
    • Table ADCs market in Americas 2015
    • Table ADCs market in Europe 2015
    • Table ADCs market in Japan 2015
  • Market drivers
    • Robust late-stage pipeline
    • Rising prevalence of cancers
      • Table Global incidence of cancer 2015 and 2020
    • Increase in demand for antibody conjugates
    • Reimbursement policies
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • High developmental costs
    • Stringent regulations
    • Risk of side effects
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Strategic alliances
    • Increased outsourcing of drug development
    • Emergence of targeted and combination therapies
  • Vendor landscape
    • Competitive scenario
    • Key news
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche: Pharmaceutical division segmentation by revenue 2015
      • Table F. Hoffmann-La Roche: ADC segmentation by revenue 2015
      • Table F. Hoffmann-La Roche: Revenue generated from net product sales of Kadcyla 2013-2015 ($ millions)
      • Table F. Hoffmann-La Roche: Geographical segmentation of Kadcyla by revenue 2015
      • Table F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in US 2013-2015 ($ millions)
      • Table F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in Europe 2014 and 2015 ($ millions)
      • Table F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in Japan 2014-2015 ($ millions)
      • Table F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in ROW 2013-2015 ($ millions)
      • Table F. Hoffmann La-Roche: Kadcyla pipeline products
      • Table F. Hoffmann La-Roche: Key takeaways
    • Seattle Genetics
      • Table Seattle Genetics: YoY revenue and growth rate of ADCETRIS in US and Canada ($ millions)
      • Table Seattle Genetics: ADCETRIS developmental pipeline
      • Table Seattle Genetics: ADCs pipeline and seven clinical trial programs
      • Table Seattle Genetics: ADC collaborations
      • Table Seattle Genetics: Key takeaways
    • Takeda Pharmaceuticals
      • Table Takeda: Business segmentation by revenue 2015
      • Table Takeda Pharmaceuticals: Geographical segmentation by revenue 2015
      • Table Takeda Pharmaceuticals: YoY growth and revenue generated from ADCETRIS (except US and Canada) 2013-2015 ($ millions)
      • Table Takeda Pharmaceuticals: Key takeaways
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report